These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
79 related articles for article (PubMed ID: 5004602)
21. Effects of isoniazid and of ceforanide against virulent tubercle bacilli in cultured human macrophages. Crowle AJ; Sbarbaro JA; May MH Tubercle; 1988 Mar; 69(1):15-25. PubMed ID: 3140456 [TBL] [Abstract][Full Text] [Related]
22. The Mycobacterium tuberculosis iniA gene is essential for activity of an efflux pump that confers drug tolerance to both isoniazid and ethambutol. Colangeli R; Helb D; Sridharan S; Sun J; Varma-Basil M; Hazbón MH; Harbacheuski R; Megjugorac NJ; Jacobs WR; Holzenburg A; Sacchettini JC; Alland D Mol Microbiol; 2005 Mar; 55(6):1829-40. PubMed ID: 15752203 [TBL] [Abstract][Full Text] [Related]
23. [Studies on the emergence of resistance of tubercle bacilli to 4-chloroanilide of 5-chlorosalicylic cid in vitro]. Kostrzeński W; Paklerska-Pobratyn H Gruzlica; 1967 Dec; 35(12):1279-84. PubMed ID: 4965764 [No Abstract] [Full Text] [Related]
24. [Studies on earlier detection of mycobacterial growth by application of STC (2,3-diphenyl-5-thienyl-(2)-tetrazolium chloride]. Osato T; Shimizu H Kekkaku; 1971 Aug; 46(8):335-40. PubMed ID: 4998864 [No Abstract] [Full Text] [Related]
25. Altered expression of isoniazid-regulated genes in drug-treated dormant Mycobacterium tuberculosis. Karakousis PC; Williams EP; Bishai WR J Antimicrob Chemother; 2008 Feb; 61(2):323-31. PubMed ID: 18156607 [TBL] [Abstract][Full Text] [Related]
26. [Variability of the polyresistance of the tubercle bacillus. I. Sensitivity to the paminosalicylic salt of isoniazid]. VIALLIER J; CAYRE RM C R Seances Soc Biol Fil; 1958; 152(7):1127-9. PubMed ID: 13619195 [No Abstract] [Full Text] [Related]
27. In vitro activity of protegrin-1 and beta-defensin-1, alone and in combination with isoniazid, against Mycobacterium tuberculosis. Fattorini L; Gennaro R; Zanetti M; Tan D; Brunori L; Giannoni F; Pardini M; Orefici G Peptides; 2004 Jul; 25(7):1075-7. PubMed ID: 15245864 [TBL] [Abstract][Full Text] [Related]
28. In vitro and in vivo activities of acylated derivatives of isoniazid against mycobacterium tuberculosis. Hearn MJ; Cynamon MH Drug Des Discov; 2003; 18(4):103-8. PubMed ID: 15553921 [TBL] [Abstract][Full Text] [Related]
29. [Biological effects of new PAS derivatives on Mycobacterium tuberculosis]. Ertan M; Saygun N; Ureten M Mikrobiyol Bul; 1985 Jul; 19(3):121-6. PubMed ID: 3929034 [TBL] [Abstract][Full Text] [Related]
30. [Significance of drug-resistant tubercle bacilli in the appearance of complications after pulmonary resection]. DANBARA H; OGAWA Y; HASHIMOTO H; YOSHITATSU S; TSUBOI K; MATSUNAGA K; ABO S; SAEKI B Iryo; 1962 Sep; 16():430-7. PubMed ID: 14024855 [No Abstract] [Full Text] [Related]
31. [Correlation of lipid fractions, toxicity and virulence of M. tuberculosis isolated from patients treated with antibacterial preparations]. Nemsadze MN Probl Tuberk; 1971; 49(11):66-9. PubMed ID: 5004859 [No Abstract] [Full Text] [Related]
32. [Studies on tubercle bacilli and their contaminant bacteria in the sputum of pulmonary tuberculosis after chemotherapy ]. Sakai I Hokkaido Igaku Zasshi; 1982 Mar; 57(2):211-6. PubMed ID: 6811390 [TBL] [Abstract][Full Text] [Related]
33. [Resistance of tubercle bacilli to streptomycin, PAS & isoniazid]. KRAAN JK Ned Tijdschr Geneeskd; 1958 Nov; 102(47):2314-8. PubMed ID: 13622796 [No Abstract] [Full Text] [Related]
34. Design and synthesis of antituberculars: preparation and evaluation against Mycobacterium tuberculosis of an isoniazid Schiff base. Hearn MJ; Cynamon MH J Antimicrob Chemother; 2004 Feb; 53(2):185-91. PubMed ID: 14688045 [TBL] [Abstract][Full Text] [Related]
35. Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-resistant, Mycobacterium tuberculosis in the guinea pig. Ahmad Z; Klinkenberg LG; Pinn ML; Fraig MM; Peloquin CA; Bishai WR; Nuermberger EL; Grosset JH; Karakousis PC J Infect Dis; 2009 Oct; 200(7):1136-43. PubMed ID: 19686043 [TBL] [Abstract][Full Text] [Related]
36. A comparative study of the susceptibility to ethionamide and isoniazid of tubercle bacilli from patients never treated with ethionamide. Hok TT; Seng TK Paediatr Indones; 1967; 7(1):32-8. PubMed ID: 4963150 [No Abstract] [Full Text] [Related]
37. Isoniazid's bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth. Gumbo T; Louie A; Liu W; Ambrose PG; Bhavnani SM; Brown D; Drusano GL J Infect Dis; 2007 Jan; 195(2):194-201. PubMed ID: 17191164 [TBL] [Abstract][Full Text] [Related]
38. [Study of isoniazid-resistant tubercle bacilli. I. On the population change of isoniazid-resistant tubercle bacilli as regards their resistance to isoniazid]. NAGASHIMA M Kekkaku; 1960 Dec; 35():861-7. PubMed ID: 13727413 [No Abstract] [Full Text] [Related]
39. [Studies on tuberculosis bacilli resistant to isoniazid. I. Introduction and behavior in vitro]. DAVID H; de ALEMQUER M Acta Tuberc Scand; 1960; 39():172-84. PubMed ID: 13719982 [No Abstract] [Full Text] [Related]
40. Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations. Gumbo T; Louie A; Liu W; Brown D; Ambrose PG; Bhavnani SM; Drusano GL Antimicrob Agents Chemother; 2007 Jul; 51(7):2329-36. PubMed ID: 17438043 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]